KRAS and cancer: HSF1 is a downstream effector of the RAS-MEK pathway (Tang et al., 2015; Dai and Sampson, 2016) and KRAS-mutant cancers, due to their elevated levels of cellular stress resulting from rapid proliferation and metabolic demands, have a higher dependence on HSF1.